A ligand-drug conjugate and medical use thereof
By linking bioactive molecules such as tubulin inhibitors and topoisomerase inhibitors to the same antibody, a multi-load ADC molecule is formed, which solves the problems of low loading and drug resistance of existing ADC drugs and improves the therapeutic effect on tumor cells.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- GAN & LEE PHARM CO LTD
- Filing Date
- 2025-12-22
- Publication Date
- 2026-07-17
AI Technical Summary
Existing antibody-drug conjugates (ADCs) have problems such as low drug loading and easy development of drug resistance when treating cancer. The therapeutic effects of a single bioactive molecule ADC are uneven on different tumor cells, especially the effect is weak on resting cells, and long-term use is prone to drug resistance.
Develop a multi-load ADC molecule containing two or more cytotoxic drugs by linking bioactive molecules such as tubulin inhibitors and topoisomerase inhibitors to the same antibody to form a multi-load ADC molecule and achieve synergistic effects.
It improved the therapeutic effect on tumor cells, enhanced the killing ability of resting cells, reduced the possibility of drug resistance, and improved the therapeutic effect of ADC.
Smart Images
Figure BDA0005753471240000011 
Figure BDA0005753471240000022 
Figure BDA0005753471240000031